Kancera AB Ownership

KAN Stock  SEK 1.30  0.07  5.11%   
Kancera AB maintains a total of 79.53 Million outstanding shares. Kancera AB secures 13.72 % of its outstanding shares held by insiders and 2.86 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kancera AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Kancera Stock Ownership Analysis

About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kancera AB recorded a loss per share of 0.87. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 24th of February 2021. Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. To find out more about Kancera AB contact Thomas Olin at 46 8 50 12 60 80 or learn more at https://www.kancera.com.

Kancera AB Outstanding Bonds

Kancera AB issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kancera AB uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kancera bonds can be classified according to their maturity, which is the date when Kancera AB has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Kancera Stock Analysis

When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.